Add BrightSurf on Google Email

Cancer's game of hide-and-seek

Researchers discovered that glioblastoma (GBM) tumor cells hide the signaling molecule targeted by therapies, adding complexity to current models of drug resistance. The findings suggest alternative approaches that could improve outcomes for cancer patients and may have significant implications for therapeutic regimens.

Killer cocktail fights brain cancer

Researchers at Rockefeller University Press develop a novel two-pronged approach to combat glioblastoma, a highly aggressive form of brain cancer. By combining interleukin-12 with a CTLA-4 blocking drug, the cocktail successfully eradicated tumors in mice, showing promise for future treatment.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·DateNov 25, 2013

Incurable brain cancer gene is silenced

A Northwestern University research team has developed a drug that silences a critical gene in glioblastoma, increasing survival rates by nearly 20% and reducing tumor size. The novel therapeutic uses nanotechnology to target the gene, which plays a key role in therapy resistance.

SourceNorthwestern University·JournalScience Translational Medicine·DateOct 30, 2013

Using fat to fight brain cancer

Johns Hopkins researchers have discovered that mesenchymal stem cells derived from human adipose tissue can seek out and destroy glioblastoma cancer cells in the brain. This innovative approach may provide a new tool for accessing difficult-to-reach areas of the brain where cancer cells proliferate.

SourceJohns Hopkins Medicine·JournalPLOS ONE·DateMar 12, 2013

Fusion gene contributes to glioblastoma progression

Researchers identified a fusion between FGFR3 and TACC3 genes in human glioblastoma samples, which promoted tumor growth and progression in a mouse model. The fusion protein escaped regulation by miR-99a, indicating its potential as a prognostic marker and drug target for glioblastoma treatment.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJan 9, 2013

JCI early table of contents for Jan. 9, 2013

Researchers found a small peptide that blocks antibody recognition of desmogleins, improving cell-cell adhesion and preventing skin blistering in pemphigus vulgaris. Additionally, spironolactone reduced vascular calcification in kidney disease mice, increasing their life span. A glioblastoma fusion gene promoted tumor growth and progre...

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJan 9, 2013

Modification of tumor suppressor affects sensitivity to potential GBM treatment

A recent study published in the Proceedings of the National Academy of Sciences reveals that a modification of the tumor suppressor gene PTEN is associated with resistance to glioblastoma treatments. The research suggests that targeting PTEN modification could lead to improved treatment outcomes for patients with glioblastoma.

SourceLudwig Institute for Cancer Research·JournalProceedings of the National Academy of Sciences·DateAug 13, 2012

Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy

Researchers at Fred Hutchinson Cancer Center have successfully transplanted gene-modified blood stem cells into brain cancer patients to protect their bone marrow against chemotherapy's toxic effects. The study showed that two patients survived longer than predicted, with one remaining alive for over three years.

SourceFred Hutchinson Cancer Center·JournalScience Translational Medicine·DateMay 9, 2012

A thought-provoking new therapeutic target for brain cancer?

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor resistant to current therapies. Researchers at the University of California, San Francisco, have identified PDGFR-alpha and SULF2 as potential therapeutic targets for GBM treatment. Knocking down SULF2 expression decreased cell growth in human GBM cell lines.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateFeb 1, 2012

JCI online early table of contents: Feb. 1, 2012

A team of researchers has identified a potential new therapeutic target for the treatment of glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. They found that protein SULF2 is expressed in primary human GBM tumors and cell lines, and its expression is associated with abnormal activation of signaling pathways down...

SourceJCI Journals·JournalJournal of Clinical Investigation·DateFeb 1, 2012

Personalized gene therapies may increase survival in brain cancer patients

A University of Illinois study found that personalized prognostic tools and gene-based therapies can improve the survival and quality of life of glioblastoma patients. The researchers discovered new general and clinical-dependent gene profiles that can be used to predict patient outcomes and select targeted therapies.

How brain tumors invade

Researchers identified a key protein mutation that enables brain tumors to invade healthy brain tissue. Excessive epidermal growth factor receptor (EGFR) signals trigger the production of GBP1, rendering tumors more invasive and allowing them to spread into surrounding tissue.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·DateDec 12, 2011

Glioblastoma multiforme in the Dock

A study by Bo Hu and Shi-Yuan Cheng found that PDGFR-alpha overexpression in glioblastomas triggers a signaling cascade promoting tumor growth and invasion. Manipulating Dock180 to block this pathway inhibits PDGFR-alpha's role in glioma tumorigenesis.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateNov 14, 2011

JCI online early table of contents: Nov. 14, 2011

Researchers discovered a molecular pathway driven by PDGFR-alpha that promotes the aggressive nature of a significant proportion of glioblastomas. Overexpressed in GBMs, this pathway triggers signaling cascades leading to tumor growth and invasion. Manipulating Dock180 phosphorylation disrupts this pathway, resulting in failed tumor pr...

SourceJCI Journals·JournalJournal of Clinical Investigation·DateNov 14, 2011

Nanoparticles seek and destroy glioblastoma in mice

Scientists at Sanford-Burnham and Salk Institute developed a method to combine peptides and nanoparticles to eliminate glioblastoma in previously untreatable mouse models. The nanosystem proved effective in treating two different mouse models, curing most tumors and significantly delaying tumor development.

SourceSanford Burnham Prebys·JournalProceedings of the National Academy of Sciences·DateOct 3, 2011

What causes brain cancer?

Researchers have discovered potential regulatory networks in glioblastoma using microRNAs and transcription factors. The study identified 54 feed-forward loops with functions important to carcinogenesis and unique functions specific to each FFL.

SourceInderscience Publishers·JournalInternational Journal of Computational Biology and Drug Design·DateJul 6, 2011